[HTML][HTML] Doença renal crônica: importância do diagnóstico precoce, encaminhamento imediato e abordagem interdisciplinar estruturada para melhora do desfecho …

MG Bastos, GM Kirsztajn - Brazilian Journal of Nephrology, 2011 - SciELO Brasil
Atualmente, é amplamente aceita a definição da doença renal crônica (DRC) que se baseia
em alterações na taxa de filtração glomerular e/ou presença de lesão parenquimatosa …

Quality of life in end-stage renal disease patients

F Valderrábano, R Jofre, JM López-Gómez - American Journal of Kidney …, 2001 - Elsevier
Health-related quality of life (QOL) refers to the measure of a patient [apos] s functioning,
well-being, and general health perception in each of three domains: physical, psychological …

Oral hypoxia–inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for the treatment of anemia in patients with CKD

R Provenzano, A Besarab, CH Sun… - Clinical Journal of the …, 2016 - journals.lww.com
Results Of the 145 patients enrolled, 143 were evaluable for efficacy. Overall, 92% of
patients achieved hemoglobin response. Higher compared with lower starting doses led to …

K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification

AS Levey, J Coresh, K Bolton, B Culleton… - American Journal of …, 2002 - experts.umn.edu
Introduction: Chronic kidney disease as a public health problem. Chronic kidney disease is
a worldwide public health problem. In the United States, there is a rising incidence and …

Normalization of hemoglobin level in patients with chronic kidney disease and anemia

TB Drüeke, F Locatelli, N Clyne… - … England Journal of …, 2006 - Mass Medical Soc
Background Whether correction of anemia in patients with stage 3 or 4 chronic kidney
disease improves cardiovascular outcomes is not established. Methods We randomly …

Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney …

A Besarab, R Provenzano, J Hertel… - Nephrology Dialysis …, 2015 - academic.oup.com
Abstract Background Roxadustat (FG-4592) is an oral hypoxia-inducible factor prolyl
hydroxylase inhibitor that stimulates erythropoiesis. This Phase 2a study tested efficacy (Hb …

2015 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease

H Yamamoto, S Nishi, T Tomo, I Masakane… - Renal Replacement …, 2017 - Springer
Renal anemia is a complication of chronic kidney disease. Guidelines for safe and effective
treatment in patients with renal anemia are needed. The Japanese Society for Dialysis …

Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease

SC Palmer, SD Navaneethan, JC Craig… - Annals of internal …, 2010 - acpjournals.org
Background: Previous meta-analyses suggest that treatment with erythropoiesis-stimulating
agents (ESAs) in chronic kidney disease (CKD) increases the risk for death. Additional …

Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition …

C Hsu, CE McCulloch, GC Curhan - Journal of the american …, 2002 - journals.lww.com
Anemia associated with chronic renal insufficiency (CRI) may have substantial clinical and
public health importance, but little is known about its epidemiology. This study aims to …

Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy

J Crawford, D Cella, CS Cleeland… - … Journal of the …, 2002 - Wiley Online Library
BACKGROUND Hemoglobin increases have been associated with quality of life (QOL)
improvements in anemic cancer patients treated with epoetin alfa, but intervention generally …